CTOs on the Move

Respicardia

www.respicardia.com

 
Founded in 2006 and headquartered near Minneapolis, Minnesota, Respicardia® is dedicated to improving the lives of heart failure patients by developing implantable therapies designed to improve Respiratory Rhythm Management and cardiovascular health. The remedē® System is an innovative implantable stimulation device designed to restore natural breathing during sleep for patients with Central Sleep Apnea.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million
  • www.respicardia.com
  • 12400 Whitewater Dr Suite 150
    Minnetonka, MN USA 55343
  • Phone: 952.540.4470

Executives

Name Title Contact Details

Funding

Respicardia raised $58.5M on 12/19/2017

Similar Companies

AWAK Technologies

AWAK is a patient-centric medical technology company with a mission to enhance the lives of dialysis patients and their caregivers by providing solutions to deliver better outcomes along with improving their quality of life.

Dedham Medical Assoc

Dedham Medical Assoc is a Dedham, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

ArthroCare Corporation

ArthroCare Corporation (ArthroCare) is a medical device company that develops, manufactures and markets surgical products, many of which are based on its Coblation technology. The Company markets surgical products across three business units: ArthroCare

Pennsylvania Occupational Therapy Association (POTA)

Pennsylvania Occupational Therapy Association (POTA) is a Harrisburg, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Proof Diagnostics

At Proof, we believe that knowledge is power—and good health is a necessity. We`re a health technology and diagnostics company that is currently developing a cutting-edge, CRISPR-based platform for point-of-care facilities to test for COVID-19, with ambitions to transform in-home diagnostics across a broad spectrum of health applications in the future. Proof is the brainchild of Professor Feng Zhang, a world-renowned molecular biologist and leader of a research lab at the Broad Institute of MIT and Harvard. In early 2020, Dr. Zhang along with Dr. Jonathan Gootenberg and Dr. Omar Abudayyeh of the McGovern Institute pivoted their focus towards combating the emergent threat of the COVID-19 pandemic. Pioneers of the CRISPR gene-editing technology, the three scientists dropped everything to face the global public health crisis head on. Combining CRISPR and RT-LAMP technologies in a novel approach, our scientific team is developing a simple, streamlined molecular diagnostics platform that can quickly test for the presence of the SARS-CoV-2 virus. Intended for use within clinics, pharmacies, schools, workplaces and eventually homes, our easy-to-use, lab-quality test platform is undergoing rigorous R&D protocols so that we can provide fast, accurate diagnostics that will help communities take control of their health. We want to transform the anxiety of waiting days for COVID-19 test results into the peace of mind of quickly knowing what steps to take next. Our first test system, which we`re designing to detect SARS-CoV-2, will enable us to fulfill our mission of helping restore a degree of normalcy to our world. From there, we aim to transform personalized health, and expand our diagnostic platform to detect other diseases, with the goal of providing actionable health information that will allow people to lead better, healthier lives. If you`re with us, reach out today.